LIVN vs. PEN, STVN, IRTC, BLCO, GKOS, TMDX, SLNO, NVST, WRBY, and INSP
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), Warby Parker (WRBY), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry.
LivaNova vs. Its Competitors
Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.
88.9% of Penumbra shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 4.2% of Penumbra shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Penumbra had 13 more articles in the media than LivaNova. MarketBeat recorded 14 mentions for Penumbra and 1 mentions for LivaNova. LivaNova's average media sentiment score of 1.13 beat Penumbra's score of 0.25 indicating that LivaNova is being referred to more favorably in the news media.
LivaNova has lower revenue, but higher earnings than Penumbra. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
Penumbra currently has a consensus target price of $302.81, suggesting a potential upside of 21.45%. LivaNova has a consensus target price of $59.71, suggesting a potential upside of 11.14%. Given Penumbra's stronger consensus rating and higher probable upside, analysts plainly believe Penumbra is more favorable than LivaNova.
Penumbra has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
Penumbra has a net margin of 11.54% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Penumbra's return on equity.
Summary
Penumbra beats LivaNova on 12 of the 17 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
LivaNova Competitors List
Related Companies and Tools
This page (NASDAQ:LIVN) was last updated on 10/18/2025 by MarketBeat.com Staff